Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

被引：15

作者：

Danielli, Riccardo ^{[1
]}

Fonsatti, Ester ^{[1
]}

Calabro, Luana ^{[1
]}

Di Giacomo, Anna Maria ^{[1
]}

Maio, Michele ^{[1
]}

机构：

[1] Univ Hosp Siena, Dept Oncol, Div Med Oncol & Immunotherapy, Ist Toscano Tumori, I-53100 Siena, Italy

来源：

THYMOSINS IN HEALTH AND DISEASE II | 2012年 / 1270卷

关键词：

thymosin alpha 1; melanoma; immunotherapy; dacarbazine; METASTATIC MELANOMA; INTERFERON-ALPHA; CANCER; COMBINATION; THERAPY; DACARBAZINE; IPILIMUMAB; SURVIVAL; BRAF;

D O I：

10.1111/j.1749-6632.2012.06757.x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Thymosin alpha 1 (T alpha 1) is an immunomodulatory peptide released by the thymus gland in mammals. It was first described in 1977 as a potential agent for the treatment of immune deficiencies and cancer. Among solid tumors, a number of clinical trials have investigated the activity of T alpha 1 in melanoma. In particular, a large randomized phase II trial that evaluated the safety and efficacy of combining T alpha 1 with dacarbazine and interferon alpha in metastatic melanoma patients provided the rationale for further clinical applications. The main findings emerging from clinical trials and that support the therapeutic use of T alpha 1 in human melanoma are summarized and discussed.

引用

页码：8 / 12

页数：5

共 24 条

[1] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].

Balch, CM ;

Soong, SJ ;

Gershenwald, JE ;

Thompson, JF ;

Reintgen, DS ;

Cascinelli, N ;

Urist, M ;

McMasters, KM ;

Ross, MI ;

Kirkwood, JM ;

Atkins, MB ;

Thompson, JA ;

Coit, DG ;

Byrd, D ;

Desmond, R ;

Zhang, YT ;

Liu, PY ;

Lyman, GH ;

Morabito, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634

[2] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[3]

Danielli R., SINGLE CTR EXP UNPUB

[4] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial [J].

Di Giacomo, Anna Maria ;

Ascierto, Paolo A. ;

Pilla, Lorenzo ;

Santinami, Mario ;

Ferrucci, Pier Francesco ;

Giannarelli, Diana ;

Marasco, Antonella ;

Rivoltini, Licia ;

Simeone, Ester ;

Nicoletti, Stefania V. L. ;

Fonsatti, Ester ;

Annesi, Diego ;

Queirolo, Paola ;

Testori, Alessandro ;

Ridolfi, Ruggero ;

Parmiani, Giorgio ;

Maio, Michele .

LANCET ONCOLOGY, 2012, 13 (09) :879-886

[5] Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) [J].

Di Giacomo, Anna Maria ;

Danielli, Riccardo ;

Calabro, Luana ;

Bertocci, Erica ;

Nannicini, Chiara ;

Giannarelli, Diana ;

Balestrazzi, Angelo ;

Vigni, Francesco ;

Riversi, Valentina ;

Miracco, Clelia ;

Biagioli, Maurizio ;

Altomonte, Maresa ;

Maio, Michele .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) :467-477

[6] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial [J].

Eggermont, Alexander M. M. ;

Suciu, Stefan ;

Santinami, Mario ;

Testori, Alessandro ;

Kruit, Wim H. J. ;

Marsden, Jeremy ;

Punt, Cornelis J. A. ;

Sales, Francois ;

Gore, Martin ;

MacKie, Rona ;

Kusic, Zvonko ;

Dummer, Reinhard ;

Hauschild, Axel ;

Musat, Elena ;

Spatz, Alain ;

Keilholz, Ulrich .

LANCET, 2008, 372 (9633) :117-126

[7] COMBINATION TREATMENT USING THYMOSIN ALPHA-1 AND INTERFERON AFTER CYCLOPHOSPHAMIDE IS ABLE TO CURE LEWIS LUNG-CARCINOMA IN MICE [J].

GARACI, E ;

MASTINO, A ;

PICA, F ;

FAVALLI, C .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 32 (03) :154-160

[8] Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a [J].

Garaci, E ;

Lopez, M ;

Bonsignore, G ;

DellaGiulia, M ;

DAprile, M ;

Favalli, C ;

Rasi, G ;

Santini, S ;

Capomolla, E ;

Vici, P ;

DiLauro, L .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2403-2405

[9]

Giuliani C, 2000, EUR J IMMUNOL, V30, P778, DOI 10.1002/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO

[10]

2-I

← 1 2 3 →